Literature DB >> 30293128

Functional Behavior-Based Cognitive-Behavioral Therapy for Obsessive Compulsive Behavior in Children with Autism Spectrum Disorder: A Randomized Controlled Trial.

Tricia Vause1, Heather Jaksic2,3, Nicole Neil2,4, Jan C Frijters5, Grazyna Jackiewicz6, Maurice Feldman7.   

Abstract

Children with autism spectrum disorder (ASD) experience obsessions and compulsions similar to those specified in DSM-5 for obsessive compulsive disorder yet little controlled research exists on treating these behaviours. Thirty-seven children (7-13 years old) were randomly assigned to a 9-week functional behavior-based cognitive behavior therapy (Fb-CBT) or Treatment As Usual. Independent assessors administered measures pre- and post-treatment and at 6-months. Two primary outcome measures indicated statistically significant differences between groups, with large corrected effect sizes (Hedge's g = 1.00 and 1.15, respectively). This is the first known RCT to exclusively treat obsessive compulsive behaviors (OCBs) in children and youth with high functioning (IQ ≥ 70) ASD, and suggests that Fb-CBT treatment shows promise in decreasing these behaviors and improving quality of life. Trial Registration This trial was registered with ClinicalTrials.gov (ID: NCT03123146).

Entities:  

Keywords:  Autism spectrum disorder; Cognitive-behavioral therapy; Function-based assessment; Obsessive compulsive behavior; Treatment

Year:  2020        PMID: 30293128     DOI: 10.1007/s10803-018-3772-x

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  2 in total

Review 1.  Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD).

Authors:  Sarah J Elliott; David Marshall; Karen Morley; Eleonora Uphoff; Mrityunjai Kumar; Nicholas Meader
Journal:  Cochrane Database Syst Rev       Date:  2021-09-03

2.  Pediatric Tuina in children with autism spectrum disorder: a study protocol for a randomized controlled trial.

Authors:  Xiang Feng; Quanrui Jiang; Yuxing Zhang; Tao Li; Wei Wei; Jun Yu; Wu Li; Jiangshan Li
Journal:  Trials       Date:  2022-01-25       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.